Unexpected Clinical Trial Events: FDA Clarifies Sponsors’ Obligations To IRBs

FDA guidelines issued Jan. 15 put the onus on device and drug trial sponsors to identify which adverse events that arise during clinical studies need to be reported to institutional review boards